Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(26 sites)
United States
Local Institution - 601, Los Angeles, California New York Presbyterian Hospital, New York, New York China
Southern Medical University Nanfang Hospital, Guangzhou, Guangdong Shenzhen Second People's Hospital, Shenzhen, Guangdong People's Liberation Army The 923rd Hospital, Nanning, GX West China Hospital - Sichuan University, Chengdu, Sichuan Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, Guangzhou The First Affiliated Hospital of Guangxi Medical University, Nanning Germany
Universitätsklinikum Essen, Essen Universitatsklinikum Ulm, Ulm Greece
General Children's Hospital "Agia Sophia", Athens India
Kamala Hospital and Research Center, Hyderabad, Andhra Pradesh MCGM - Comprehensive Thalassemia Care, Pediatric Hematology-Oncology & BMT Centre, Borivali (E), Mumbai, Maharashtra Kingsway Hospitals, Nagpur, Maharashtra Post Graduate Institute of Child Health, Noida, Uttar Pradesh Local Institution - 803, Kolkata Christian Medical College & Hospital, Vellore Italy
Ospedale Pediatrico Bambino Gesù IRCCS, Rome, Roma Ente Ospedaliero Ospedali Galliera - Centro della Microcitemia e delle Anemie Congenite, Genoa AOU dell'Universita degli Studi della Campania Luigi Vanvitelli, Naples Azienda Ospedaliero Universitaria S. Luigi Gonzaga, Orbassano Lebanon
Local Institution - 700, Beirut Thailand
Chulalongkorn University Faculty of Medicine - King Chulalongkorn Memorial Hospital, Bangkok Siriraj Hospital Mahidol University, Bangkok Ramathibodi Hospital, Mahidol University, Phyathai Turkey (Türkiye)
Local Institution - 401, Izmir Age range
6 Years – 17 Years
Last updated January 2026